OCA
CCXI

Octagon Capital Advisors’s ChemoCentryx, Inc. CCXI Stock Holding History

Octagon Capital Advisors’s Portfolio CCXI Stock Details CCXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-150,076
Closed -$7.69M – 36
2021
Q1 		$7.69M Sell
150,076
-75,000
-33% -$4.51M 2.9% 14
2020
Q4 		$13.9M Buy
+225,076
New +$12.9M 4.83% 10

Other funds holding CCXI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Octagon Capital Advisors's CCXI Position: Q2 2021 in Review

Octagon Capital Advisors sold out of ChemoCentryx, Inc. (CCXI) in Q2 2021, closing a stake of 150,076 shares — an estimated $7.69M sold.

Octagon Capital Advisors first reported a position in CCXI in Q4 2020 and held it in 2 quarters. The position peaked at $13.9M in Q4 2020. 146 funds tracked by Wall St. Rank hold CCXI as of Q2 2021.

  • Octagon Capital Advisors reported no remaining ChemoCentryx, Inc. position as of Q2 2021 after selling out during the quarter.
  • Octagon Capital Advisors sold 150,076 ChemoCentryx, Inc. shares in Q2 2021, an estimated $7.69M.
  • Octagon Capital Advisors first reported a position in ChemoCentryx, Inc. in Q4 2020 and held it in 2 quarters.
  • Octagon Capital Advisors's ChemoCentryx, Inc. position peaked at $13.9M in Q4 2020.
  • 146 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q2 2021.

Based on Octagon Capital Advisors's 13F filing for Q2 2021, filed 16 Aug 2021.